glp 1 agonist effects Frontiers Glucagon-like peptide 1(GLP-1) receptor agonists

The most consistent lipid change observed with GLP-1 therapy is a reduction in triglycerides , typically ranging from 10-20% in clinical studies

In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]

Mentis N, Vardarli I, Kthe LD, Holst JJ, Deacon CF, Theodorakis M, et al

Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10,246 patients with type 2 diabetes

Gynecol Endocrinol (2023) 39(1):2181652

311, no